D
Duquesne Family Office LLC
+ HältPURR
+8.54%
3-Monats-Rendite
$9.070
-0.676 (-7.45%)Zum Schluss
Loading chart…
- Hoch
- 9.730
- Eröffnung
- 9.610
- Volumengewichteter Durchschnittskurs
- 9.26
- Volumen
- 11.77M
- Marktkap.
- —
- Tief
- 8.980
- Umsatz
- 108.98M
- EV/EBITDA, TTM
- 0.37
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action.
KI-Analyse of Hyperliquid Strategies Inc (PURR)
HaltenHyperliquid Strategies Inc (PURR) is currently priced at $9.07, which is significantly below the analyst price target of $18, suggesting potential upside. However, the stock has seen a drastic 35.63% decline over the last 20 days and an RSI of 20.16 indicates it is oversold. The company has shown a strong revenue increase from $500,000 in Q2 to $6,334,000 in Q4, indicating improving financial performance. The main risk is the negative net income of $1,212,921,000 in Q1, which raises concerns about profitability.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Hyperliquid Strategies Inc (PURR) beträgt 14.20, verglichen mit dem 5-Jahres-Durchschnitt von 14.20.
Whales, die PURR halten
Event-Zeitleiste
News
8.510-16CNBCValuation Gap Widens Between AI Leaders OpenAI and Anthropic
7.009-29CNBCHouse Expands Investigation into Insider Trading in Prediction Markets
6.009-15CNBCLatest Rating Updates from Wall Street
8.509-15stocktwitsCompass Point Initiates Coverage on Hyperliquid Strategies with Buy Rating
2.009-07NASDAQ.COMHyperliquid Strategies Surges 94% in August 2026
PURR FAQ – beantwortet von Alphio AI
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. It operates in the Technology sector.
Hyperliquid Strategies Inc (PURR) is currently priced at $9.07, which is significantly below the analyst price target of $18, suggesting potential upside. However, the stock has seen a drastic 35.63% decline over the last 20 days and an RSI of 20.16 indicates it is oversold. The company has shown a strong revenue increase from $500,000 in Q2 to $6,334,000 in Q4, indicating improving financial performance. The main risk is the negative net income of $1,212,921,000 in Q1, which raises concerns about profitability.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.